Mitsutaka Nishimoto

Dr. Mitsutaka Nishimoto

Osaka City University, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2014 in Infection
Verified
Journal Article
Closed access
PDF file
MAMizuki Aimoto
Mizuki Aimoto
HKHideo Koh
Hideo Koh
TKTakako Katayama
Takako Katayama
HOHiroshi Okamura
Hiroshi Okamura
TYTakuro Yoshimura
Takuro Yoshimura
MHMasayuki Hino
Masayuki Hino

25 November 2022 in Cytotherapy
Verified
Journal Article
Closed access
MLMi-Ae Lyu
Mi-Ae Lyu
MHMeixian Huang
Meixian Huang
KZKe Zeng
Ke Zeng
LLLi Li
Li Li
JKJoseph D. Khoury
Joseph D. Khoury
SPSimrit Parmar
Simrit Parmar

10 April 2011 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HKHideo Koh
Hideo Koh
HNHirohisa Nakamae
Hirohisa Nakamae
KHKiyoyuki Hagihara
Kiyoyuki Hagihara
TNTakahiko Nakane
Takahiko Nakane
MMMasahiro Manabe
Masahiro Manabe
MHMasayuki Hino
Masayuki Hino
Background: There has been insufficient examination of the factors affecting long-term survival of more than 5 years in patients with leukemia that is not in remission at transplantation. Method: We retrospectively analyzed leukemia not in remission at allogeneic hematopoietic cell transplantation (allo-HCT) performed at our institution between January 1999 and July 2009. Forty-two patients with a median age of 39 years received intensified conditioning (n = 9), standard (n = 12) or reduced-intensity conditioning (n = 21) for allo-HCT. Fourteen patients received individual chemotherapy for cytoreduction during the three weeks prior to reduced-intensity conditioning. Diagnoses comprised acute leukemia (n = 29), chronic myeloid leukemia-accelerated phase (n = 2), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) (n = 10) and plasma cell leukemia (n = 1). In those with acute leukemia, cytogenetic abnormalities were intermediate (44%) or poor (56%). The median number of blast cells in bone marrow (BM) was 26.0% (range; 0.2-100) before the start of chemotherapy for allo-HCT. Six patients had leukemic involvement of the central nervous system. Stem cell sources were related BM (7%), related peripheral blood (31%), unrelated BM (48%) and unrelated cord blood (CB) (14%). Results: Engraftment was achieved in 33 (79%) of 42 patients. Median time to engraftment was 17 days (range: 9-32). At five years, the cumulative probabilities of acute graft-versus-host disease (GVHD) and chronic GVHD were 63% and 37%, respectively. With a median follow-up of 85 months for surviving patients, the five-year Kaplan-Meier estimates of leukemia-free survival rate and overall survival (OS) were 17% and 19%, respectively. At five years, the cumulative probability of non-relapse mortality was 38%. In the univariable analyses of the influence of pre-transplant variables on OS, poor-risk cytogenetics, number of BM blasts (>26%), MDS overt AML and CB as stem cell source were significantly associated with worse prognosis (p = .03, p = .01, p = .02 and p < .001, respectively). In addition, based on a landmark analysis at 6 months post-transplant, the five-year Kaplan-Meier estimates of OS in patients with and without prior history of chronic GVHD were 64% and 17% (p = .022), respectively. Conclusion: Graft-versus-leukemia effects possibly mediated by chronic GVHD may have played a crucial role in long-term survival in, or cure of active leukemia.

26 August 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SFShigeo Fuji
Shigeo Fuji
HNHirohisa Nakamae
Hirohisa Nakamae
JSJunichi Sugita
Junichi Sugita
YNYuho Najima
Yuho Najima
TKTatsuya Konishi
Tatsuya Konishi
KYKimikazu Yakushijin
Kimikazu Yakushijin

14 May 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JNJoji Nagasaki
Joji Nagasaki
MNMitsutaka Nishimoto
Mitsutaka Nishimoto
HKHideo Koh
Hideo Koh
HOHiroshi Okamura
Hiroshi Okamura
MNMika Nakamae
Mika Nakamae
HNHirohisa Nakamae
Hirohisa Nakamae

8 May 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
SIShintaro Izumi
Shintaro Izumi
KOKo Ohtani
Ko Ohtani
MMMakoto Matsumoto
Makoto Matsumoto
SSSeito Shibata
Seito Shibata
BRBahityar Rahmutulla
Bahityar Rahmutulla
THTakayuki Hoshii
Takayuki Hoshii
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.